THE POTENTIAL OF ACOUSTIC CLUSTER THERAPY (ACT®) TECHNOLOGY PLATFORM TO BE PRESENTED AT ESMO TARGETED ANTICANCER THERAPIES VIRTUAL CONGRESS 2021
EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Company”), a clinical stage precision medicine company today announced that its proprietary Acoustic Cluster Therapy (ACT®) platform technology for targeted therapeutic enhancement will be the subject of a presentation at the forthcoming ESMO Targeted Anticancer Therapies (TAT) Virtual Congress 2021.
The ESMO Targeted Anticancer Therapies Virtual Congress 2021 is set to offer participants a glimpse of the future of targeted anticancer therapies and is the premier international meeting focusing on promising new anticancer targets and agents, with a particular focus on those in early phase clinical development.
The presentation will take place on March 1st 2021 and will focus on the background and rationale of ACT®, preclinical study data and the ongoing Phase I evaluation. The Phase I ACTIVATE study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ACT® when co-administered with standard of care chemotherapy in patients with metastatic colorectal cancer.
Title: Acoustic cluster therapy (ACT) as a mechanism of increasing drug delivery: Phase I experience (ID50)
Presenting Author: Prof Udai Banerji, NIHR Professor of Molecular Cancer Pharmacology at The Institute of Cancer Research, London, and Honorary Consultant in Medical Oncology, Royal Marsden Hospital NHS Foundation Trust.
Session: (Educational) Nothing is undruggable! (ID19)
Date/Time: Monday 1st March 2021/ 13.00-13.15
The Targeted Anticancer Therapies 2021 Virtual Congress 2021 will bring together experts in anticancer drug discovery and clinical development, translational scientists, and regulators in a unique forum to highlight recent advances and new data, whilst promoting collaboration and knowledge-sharing in a bench-to-bedside approach.The TAT meeting is a meeting focused on early clinical trials and has been described as ‘The home of phase I in oncology’. This meeting will be entirely dedicated to improving the conduct of early anti-cancer clinical trials, with presentations, discussions and educational reviews and workshops highlighting emerging pre-clinical and clinical data, as well as defining optimal methodologies for early clinical trials.
About ACT®
• ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
• ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
• Initial focus of the company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.
About EXACT
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com
For more information contact:
Dr Rafiq Hasan,
CEO EXACT Therapeutics
Richard Hayhurst/Janet Joy
Tel +44 7711 821527